Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors
Jennifer A. Chan, Susan M. Geyer, Tyler Zemla, et al.
New England Journal of Medicine (2024)
Closed Access | Times Cited: 19

Showing 19 citing articles:

Pulmonary neuroendocrine neoplasms: the molecular landscape, therapeutic challenges, and diagnosis and management strategies
Triparna Sen, Yosuke Dotsu, Virginia Corbett, et al.
The Lancet Oncology (2025) Vol. 26, Iss. 1, pp. e13-e33
Closed Access | Times Cited: 3
Mixed Neuroendocrine Non-Neuroendocrine Neoplasm combining Neuroendocrine tumor with Hepatocellular Carcinoma in the context of Multiple Endocrine Neoplasia type 1
Madeleine Mulsant, Jean‐François Mosnier, Éric Frampas, et al.
Clinics and Research in Hepatology and Gastroenterology (2025) Vol. 49, Iss. 2, pp. 102533-102533
Closed Access | Times Cited: 1
Theranostics in Lung Neuroendocrine Tumors
Indraja D. Dev, Ameya Puranik, Nikolaos A. Trikalinos, et al.
Seminars in Nuclear Medicine (2025)
Closed Access | Times Cited: 1
Vascular Endothelial Growth Factor Receptors in the Vascularization of Pancreatic Tumors: Implications for Prognosis and Therapy
C.J. Grobbelaar, Vanessa Steenkamp, Peace Mabeta
Current Issues in Molecular Biology (2025) Vol. 47, Iss. 3, pp. 179-179
Open Access | Times Cited: 1
Systemic Therapy for Patients with Metastatic Pheochromocytoma and Paraganglioma
Alessa Fischer, Jaydira Del Rivero, Katharina Wang, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2025), pp. 101977-101977
Closed Access
Select updates from ASCO and ESMO 2024 for gastrointestinal cancer care
Tim Jang, George P. Kim, Thomas J. George
The Oncologist (2025) Vol. 30, Iss. 2
Open Access
Basic science and translational implications of current knowledge on neuroendocrine tumors
Lynnette Fernandez-Cuesta, Nicolas Alcala, Emilie Mathian, et al.
Journal of Clinical Investigation (2025) Vol. 135, Iss. 5
Open Access
Cabozantinib bei vorbehandelten, progredienten neuroendokrinen Tumoren

Gastroenterologie up2date (2025) Vol. 21, Iss. 01, pp. 6-6
Closed Access
Kommentar zu: Cabozantinib bei vorbehandelten, progredienten neuroendokrinen Tumoren
Anja Rinke
Gastroenterologie up2date (2025) Vol. 21, Iss. 01, pp. 6-8
Closed Access
Surufatinib in advanced neuroendocrine tumours: Final overall survival from two randomised, double-blind, placebo-controlled phase 3 studies (SANET-ep and SANET-p)
Jianming Xu, Lin Shen, Jie Li, et al.
European Journal of Cancer (2025), pp. 115398-115398
Closed Access
Gastrointestinal neuroendocrine tumor syndromes (GI-NETS)
Tetsuhide Ito, Robert T. Jensen
Elsevier eBooks (2025)
Closed Access
Tumores Neuroendocrinos Gastroenteropancreáticos
Andrés Rodríguez, Greta Catani, Oscar Andriani, et al.
Oncología Clínica (2025) Vol. 30, Iss. 1
Closed Access
Detrimental impact of gastric acid suppressants on vascular endothelial growth factor receptor tyrosine kinase inhibitors efficacy: evidence from a systematic review and meta-analysis
Jiefeng Luo, Qiong Du, Jiyong Liu
Expert Review of Clinical Pharmacology (2025)
Closed Access
Immuntherapie bei neuroendokrinen Neoplasien des Gastrointestinaltrakts
Sebastian Krug, Leonidas Apostolidis
Deleted Journal (2025)
Closed Access
Selecting optimal therapy for advanced nonfunctional pancreatic neuroendocrine tumors: latest research and therapeutic advances
Ruba Alchaikh Hassan, Arti C. Patel, Constantin A Dasanu
Expert Opinion on Pharmacotherapy (2025)
Closed Access
Cabozantinib bei vorbehandelten, progredienten neuroendokrinen Tumoren

TumorDiagnostik & Therapie (2025) Vol. 46, Iss. 04, pp. 233-234
Closed Access
Eastern Canadian Gastrointestinal Cancer Consensus Conference 2024
Jennifer Leigh, Atique U. Ahmed, F. Aubin, et al.
Current Oncology (2025) Vol. 32, Iss. 3, pp. 175-175
Open Access
The Landmark Series: Surgical Management of Functioning and Non-Functioning Pancreatic Neuroendocrine Tumors
Joseph Tobias, Callisia N. Clarke, Alexandra Gangi, et al.
Annals of Surgical Oncology (2025)
Open Access
Current status of peptide receptor radionuclide therapy in grade 1 and 2 gastroenteropancreatic neuroendocrine tumours
Jelka Kuiper, Eline Zoetelief, Tessa Brabander, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 2
CABINET presents cabozantinib as a new treatment option for NETs
David Killock
Nature Reviews Clinical Oncology (2024)
Closed Access
Treatment sequencing in gastroenteropancreatic neuroendocrine tumors
Philipp Melhorn, Markus Raderer, Barbara Kiesewetter
memo - Magazine of European Medical Oncology (2024) Vol. 17, Iss. 4, pp. 257-262
Open Access
Selecting systemic treatment for metastatic neuroendocrine tumors of the lung—current evidence and clinical implications
Philipp Melhorn, Markus Raderer, Barbara Kiesewetter
Cancer Treatment Reviews (2024) Vol. 133, pp. 102878-102878
Open Access
Page 1

Scroll to top